Raquel Díaz Francia

Starting tomorrow, AstraZeneca is on the ground at European Society of Cardiology’s Heart Failure Congress (ESC-HF) in Belgrade, hearing about the latest clinical and research developments in #heartfailure. As we continue to expand our knowledge, one thing stays true: heart failure is a complex, heterogenous and progressive condition driven by a myriad of underlying drivers and requires new targets that aim to address the root causes of disease. As research in drug design advances, we must think differently about how we target novel therapies to the right tissue. Which is why I’m delighted to hear that our colleague @Marie Ahlqvist is also boots on the ground at ELRIG’s conference this week bringing new insights on targeting delivery of oligonucleotide-based therapies to the heart. I’m proud to see teams working across AstraZeneca in lockstep to identify novel disease-causing protein variants in cardiac tissues, as well as the optimal routes for therapeutic delivery to ultimately help achieve disease modification. #WhatScienceCanDo

147

1 Kommentar

This week @Novartis in Basel, we had the privilege of welcoming Mr. Matjaž Han, Minister of the Economy, Tourism and Sport of Slovenia, together with Ambassador Iztok Grmek and a high-level delegation of government, business, and academic leaders. Building on the conversations at the Bled Strategic Forum, we focused on Europe’s competitiveness and the role of science and innovation. The EFPIA WAIT Indicator shows the scale of the challenge we all are facing: Patients in Europe wait on average 2 years longer for access to new medicines Europe’s share of global R&D investment has dropped by 25% in the last two decades Clinical trial starts are declining, and talent is moving where innovation is rewarded These are not abstract numbers — they mean patients waiting longer and Europe at risk of losing ground as a global hub for life sciences. What gives me confidence is not just the commitment, but the shared determination to turn dialogue into action. Together, we are exploring concrete steps to streamline regulation, reward innovation, and accelerate patient access. I see every day how our teams work to shorten the time from breakthrough science to patients — and how markets like Slovenia can play a pivotal role in making that ambition real. From Bled to Basel, the message is clear. A special thanks to Aymeric Royere, Country President Slovenia; Sweta Ghelani, Head ECC Cluster; Petra Štefanič Anderluh, Global Head Small Molecules; Wojciech Nowak, Head Public Affairs SERCE; and Neza Golob, Country CFO Slovenia & Site Finance Head for joining and bringing their expertise and insights to this important conversation with our Slovenian stakeholders.

200

1 Kommentar

What does patient safety actually mean? After our Patient Safety Day Daiichi Sankyo Europe GmbH, I am more convinced than ever: it is about seeing the whole person, not just the treatment. We were privileged to hear directly from Diana Dragu and Katharina Bauer about the realities shaping their lives during treatment – from fertility and lactation, to the safety of their families at home, to the need for honest conversations about future plans. These are not “side topics” – they are central to patient safety. Pharmacovigilance helps us capture these lived experiences and turn them into knowledge we can act on. Listening alone is not enough. It is our responsibility to ensure these insights lead to tangible changes – in how we design our studies, how we counsel patients, and how we make sure our approach to treatment considers real-world needs. I cannot emphasize enough that patient safety is truly a shared mission. From Medical Affairs to Pharmacovigilance, from clinical teams to affiliates, each of us plays an important role in making sure treatments are not only effective but also safe and supportive. To patients and families – what aspects of safety matter most to you during and after treatment? 

156

10 Kommentare